Profiling B cell immune responses to identify neutralizing antibodies from convalescent COVID 19 patients
Lisu Huang,Bingqing Shen,Yu Guo,Shu Shen,Heyu Huang,Qiuling Xie,Mingjie Chen,Xinxin Zeng,Shanshan Wang,Dakun Huang,Mengshi Huang,Yushu Qiu,Xiaochen Han,Qingqing Jing,Minmin Lu,Chunjiang Pi,Jia Wu,Minfang Feng,Ouyang Li,Yun-Yueh Lu,He Zhou,Cheryl Cui,Jeff He,Shuming Pan,Da Chen,Xingdong Zhou,Yuan Wang,Yujie Tian,Wei Wang,Wanju Zhang,Fei Deng,Liang Schweizer,Hongkai Zhang,Kun Sun
DOI: https://doi.org/10.21203/rs.3.rs-38173/v2
2020-01-01
Abstract:The pandemic Coronavirus Disease 2019 (COVID-19) causes noticeable morbidity and mortality worldwide. In addition to vaccine and antiviral drug therapy, the use of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) neutralizing antibodies for treatment purposes is a viable alternative. In this study, we aimed to profile the humoral responses and identify neutralizing antibodies against SARS-CoV-2 using high-throughput single-cell sequencing that tailored to B cell receptor sequencing. From two convalescent patients with high serum titer against SARS-COV-2, we identified seven antibodies specifically binding to SARS-CoV-2. Among these, the most potent antibody, P4A1 was demonstrated to block the binding of spike protein to its receptor angiotensin-converting enzyme 2 (ACE2), and prevent the viral infection in neutralization assays with pseudovirus as well as live virus at nM to sub-nM range. Moreover, antibody P4A1 can also bind strongly to spike protein with N354D/D364Y, R408I, W436R, V367F or D614G mutations respectively, suggesting that the antibody alone or in combination with other antibodies that recognize different variations of SARS-CoV-2, may provide a broad spectrum therapeutic option for COVID-19 patients. Authors Lisu Huang, Bingqing Shen, Yu Guo, and Shu Shen contributed equally to this work.